Introduction
Phencyclidine (angel dust) is a drug frequently abused by adolescents and young adults. For example, a New York State study of secondary school students indicated that 15.5% of students (276,000) had used phencyclidine [9] . Although originally developed as a short acting anesthetic, phencyclidine's sedative and hallucinogenic effects have made it a popular drug of abuse among young people of childbearing age [11] . The use of phencyclidine by pregnant women is of concern since phencyclidine has been shown to cross the placenta and to reach the fetus [13] .
There have been several reports in which phencyclidine exposure during gestation has been associated with adverse effects on the fetus. In one report, two neonates exposed in utero demonstrated a classic withdrawal syndrome [13] . They were irritable, hypertonic, jittery, and had diarrhea and vomiting for several days postpartum. A second report described neurologic and anatomic abnormalities in one infant whose mother had used large amounts of phencyclidine throughout pregnancy [2] . This infant had an abnormal neurologic examination and abnormal behavior in the neonatal period; he was jittery, irritable, hypertonic, unable to track visually, and a poor feeder. Furthermore, his appearance was unusual; he had a triangularly shaped face, eyes with an antimongoloid slant, and a pointed chin. At the age of five he had spastic quadriparesis and was severely mentally retarded.
Given the reported frequency of phencyclidine use, the fact that phencyclidine crosses the placenta, and the possibility that intrauterine exposure to phencyclidine may be harmful to the fetus, we undertook a large prospective study to describe the extent of phencyclidine use during pregnancy and the characteristics of the user population [4] . The results of consecutive screening of more than 2,000 pregnant women between 1981 and 1982 showed that 7.3 percent gave a verbal history of phencyclidine use but only 0.8 percent could be confirmed as current users by maternal urine screening [4] , The purpose of the present study was to describe the physical characteristics, neurologic findings, behavior, and neonatal clinical course of the infants of these women, and to compare them with a group of matched control infants.
Methods
All women attending the prenatal clinics affiliated with Cleveland Metropolitan General Hospital from June, 1981 through October, 1982 were questioned on their initial visit about their drug, tobacco, and alcohol use. Trained screeners took substance abuse histories [4] and administered Michigan Alcoholism Screening Tests [10] .
Study patients were defined as those who gave a verbal history of phencyclidine use during pregnancy and/or positive urine tests. Potential control patients were defined as those who did not have a history of phencyclidine use during pregnancy and whose urine tests were negative for phencyclidine. For this study, control patients were matched to study patients on maternal date of recruitment, age, ethnicity, weight, parity, weeks gestation at registration, and tobacco smoking behavior.
All patients' urines were initially screened for phencyclidine using the Enzyme Mediated Immunoassay Technique (EMIT) [1] . Specimens were initially defined as "positive" if the EMIT reading was ten units above the negative calibrator. The presence of phencyclidine was subsequently verified by gas chromatographymass spectrometry, using previously reported methodology [7] . Urines from study patients and any controls thought to be at risk for drug abuse were retested at each visit. Most of the patients had their urines tested 4 -5 times prior to delivery. Furthermore, study patients and neonates had urine and blood analyses during the intrapartum and postpartum period. All bloods were negative. The results of the pharmacological analyses have been reported separately [8] . Control patients' urines were also retested during the intrapartum period. Study and control neonates were evaluated mid feeding between 24 and 72 hours of age by a single examiner blind to the maternal history. This examiner is a certified pediatric nurse practitioner who is also a certified Brazelton examiner with additional experience screening Fetal Alcohol Syndrome infants [3] . Growth parameters, physical characteristics, neurologic findings, and behavior were documented according to a format based on previous descriptions of phencyclidine exposed infants (table I) [2, 13] . The data were analyzed in the following ways: First, descriptive statistics and paired t tests were used to compare study and control populations in regard to maternal age, race, parity, smoking behavior, and number of drugs used.
Next, a hierarchial analysis was used to examine the relationship between drug use and neonatal outcome. First, paired t tests were used to compare the total number of abnormal findings between the study and control infants and the frequency of abnormalities were plotted on histograms. Next, stepwise multiple regression techniques with nonforced variables were used to determine relationships between neonatal outcome and the seven classes of maternally abused substances (phencyclidine, narcotics, barbiturates, cocaine, marijuana, glue, and alcohol). Then, chi square tests were used to determine which of the dichotomous outcome variables were significantly different in study and control neonates. Finally, stepwise discriminant function analysis was used to relate specific outcome variable to phencyclidine use. A probability level p < 0.05 was accepted as significant.
Results
A total of 2,327 pregnant women were screened for phencyclidine use early in pregnancy. A verbal history of phencyclidine use during pregnancy was reported by 149 (6.4%) and current use was reported and/or documented in 23 (1%). Data collection was completed for 94 study patients, 14 of whom were verified users, and 94 matched controls. the entry of patients into the study. Most patients lost to follow-up were lost due to delivery at another hospital, delivery at times when examinations could not be obtained or refusal participate. The demographic characteristics of this population has been described in depth [4] and previous analysis indicated that there were no significant demographic differences between the patients studied and those lost to followup. Table III shows that study and control groups differed significantly only in the mean number of drugs used. This was true both within the total study sample and the subset of confirmed users. Both study and control patients most frequently abused marijuana, cocaine, barbituates, alcohol and glue in that order. Matching criteria were effective as both groups were found to be similar in maternal age, race, parity, and smoking behavior. Furthermore, other maternal characteristics, for which patients were not matched, were also similar in the study and control groups. Maternal education and socioeconomic status were not statistically different between study and control groups.
Patients were also similar in terms of medical obstetric risk. Antenatal risk scores (Hobel) [12] were similar after adjustment for substance abuse. Furthermore, the infants were all at term and similar in regards to intrapartum risk and apgar scores.
A significantly increased number of abnormal findings in neonates was associated with maternal phencyclidine exposure (table IV) . There the study infants averaged 5.8 + 3.3 abnormalities and the control group averaged 3.5 + 2.4 abnormalities (p < 0.02). While the means were different, the histograms (figure 1) of study and control patients, show that the distributions of abnormalities were similar in each group.
Many of the study patients were multiple drug users. However, stepwise multiple regression techniques showed that the number of abnormalities was related to phencyclidine use and not other drugs. Phencyclidine was the only substance of the seven classes of substances abused by the patients which accounted for a significant portion of the variance related to the number of abnormal findings (F = 4.38; df = 1,138; ρ < 0.05). Nevertheless, drug interactions cannot be ruled out. There were no opiate users in the study sample.
Abnormal neurological and behavioral findings were associated with maternal phencyclidine exposure (table V) . Those found significantly more often in the study group included poor attention, hypertonic ankle reflexes, and depressed neonatal reflexes -grasp and rooting. The abnormal grasp reflex was the only reflex significantly related to phencyclidine use with stepwise discriminant function analysis (F = 8.38; df = 1,174; ρ < 0.01). No significant relationships were found between abnormal anatomic findings and maternal phencyclidine use. 
Discussion
The results of this study of 188 infants suggest that infants born to women with a history of phencyclidine use during pregnancy have more abnormal neurological and behavioral findings at birth than control infants. These abnormalities are related to phencyclidine use and not to other drug use. However, interactions with other drugs cannot be ruled out. No anatomical abnormalities were detected, but the sample size may need to be much larger to see these abnormalities.
Women with a verbal history of phencyclidine use, as well as those with chemically confirmed use during pregnancy, were included in the study group for two reasons: First, phencyclidine use could be confirmed in only a small percentage of the population. This was probably due to infrequent urine testing [4] . Therefore, the frequency of phencyclidine use (which exceeds 15% in some populations [9] ) would almost certainly be underestimated and many users would have been missed if only the confirmed users had been studied. The decision to include historical and confirmed users as study patients appears justified since the numbers of abnormal findings were similar in these two groups.
The results of this study do not completely agree with what has previously been reported. These findings are similar to those of a report which described an infant exposed to phencyclidine in utero with lethargy, inability to track visually, hypertonicity, and poor feeding [2] . However, the results of the present study are different in that structural abnormalities were not found. Thus, this study suggests that phencyclidine is not an anatomic teratogen but does not confirm this. A larger sample size may be needed to see anatomical abnormalities. Furthermore, the possibility exists that study infants were not exposed to phencyclidine at the time of organ formation, or that exposure was of insufficient amount or duration to cause structural defects such as those previously reported [2] . Moreover, the earlier report involved an infant also exposed simultaneously to very high amounts of marijuana throughout gestation.
Even though phencyclidine users are almost always multiple drug abusers [4] , this study demonstrated statistically significant effects on the fetus only from phencyclidine exposure. However, previous studies have suggested a relationship between gestational exposure to barbiturates [6] , marijuana [2, 5] , and alcohol [13] and an adverse fetal outcome. In addition, past studies have shown that narcotic exposure can have severe effects on the neonates [14] .
Since none of the patients in this study were narcotics users, this study cannot address the issue of neonatal effects due to combined phencyclidine and narcotic use.
The results of this study suggest that long-term follow-up of these infants would be worthwhile. While it is unlikely that the neonatal findings would directly correlate with long-term findings, one could speculate that these children may be at increased risk of minor neurologic abnormalities and/or learning difficulties.
Our previous study indicated that phencyclidine use during pregnancy was widespread [4] . This study suggests that exposure of the fetus to phencyclidine can result in abnormal neonatal neurologic findings and behavior. Future studies must determine the long-term effects of exposing the fetus to phencyclidine.
Summary
The purpose of this study was to determine the effects of maternal phencyclidine use on the fetus. Ninety-four neonates with maternal phencyclidine exposure were compared with 94 controls. Maternal phencyclidine use was assessed by questionnaire and repeated urine testing. Mothers of study and control patients were matched for demographic characteristics. Infants were assessed between 24-72 hours postnatally by a single examiner blind to the maternal history. The results showed that study infants had a mean of 5.02 + 2.93 abnormalities while controls had a mean of 4.13 ± 2.65 abnormalities (p < 0.01). Furthermore, study infants were more likely than controls to have poor attention, hypertonia, and depressed neonatal reflexes (p < 0.05). The contribution of seven drug classes to the total number of abnormalities was assessed using stepwise multiple regression. Only phencyclidine accounted for a significant proportion of the variance (f = 4.38; p < 0.05). The results of this study suggest that maternal phencyclidine use may lead to abnormal neonatal neurologic findings and behavior.
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